CSIMarket
 


Elutia Inc   (ELUT)
Other Ticker:  
 
 

ELUT's Revenue Growth by Quarter and Year

Elutia Inc 's Revenue results by quarter and year




ELUT Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter June - 9.98 12.64 12.16
III Quarter March 5.84 13.05 11.50 12.88
II Quarter December 6.53 12.67 10.86 -11.77
I Quarter September 5.84 12.39 11.49 11.77
FY   18.21 48.09 46.49 25.04



ELUT Revenue third quarter 2023 Y/Y Growth Comment
Elutia Inc reported drop in Revenue in the third quarter 2023 by -55.23% to $ 5.84 millions, from the same quarter in 2022.
The fall in the third quarter 2023 Elutia Inc 's Revenue compares unfavorably to the Company's average Revenue increase of 13.72%.

Looking into third quarter 2023 results within Biotechnology & Pharmaceuticals industry 14 other companies have achieved higher Revenue growth. While Elutia Inc ' s Revenue meltdown of -55.23% ranks overall at the positon no. 1223 in the third quarter 2023.




ELUT Revenue ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter June - -21.04 % 3.95 % -
III Quarter March -55.23 % 13.48 % -10.71 % -
II Quarter December -48.46 % 16.67 % - -
I Quarter September -52.87 % 7.83 % -2.38 % -
FY   - 3.44 % 85.66 % -

Financial Statements
Elutia Inc 's third quarter 2023 Revenue $ 5.84 millions ELUT's Income Statement
Elutia Inc 's third quarter 2022 Revenue $ 13.05 millions Quarterly ELUT's Income Statement
New: More ELUT's historic Revenue Growth >>


ELUT Revenue (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter June - -23.52 % 9.91 % -5.59 %
III Quarter March -10.52 % 3 % 5.89 % -
II Quarter December 11.82 % 2.26 % -5.48 % -
I Quarter September -41.48 % -1.98 % -5.51 % -
FY (Year on Year)   - 3.44 % 85.66 % -




Revenue third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #15
Healthcare Sector #215
Overall #1223

Revenue Y/Y Growth Statistics
High Average Low
91.41 % 13.72 % -44.44 %
(Sep 30 2022)   (Mar 31 2024)
Revenue third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #15
Healthcare Sector #215
Overall #1223
Revenue Y/Y Growth Statistics
High Average Low
91.41 % 13.72 % -44.44 %
(Sep 30 2022)   (Mar 31 2024)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Elutia Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
11.8 % -5.1 % -41.47 %
(Dec 31 2023)  


ELUT's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2023 Elutia Inc reported drop in Revenue sequentially by -10.52% to $ 5.84 millions, from $ 6.53 millions released a quarter before.

Those cyclical influence could not salvage the III. Quarter for the Elutia Inc , Mason King, an industry expert based in Boston pointed out, he detected new challenges onward for the Biotechnology & Pharmaceuticals's company and mentioned that average sequential Revenue growth is at -5.1% for the Biotechnology & Pharmaceuticals's company.

Within Biotechnology & Pharmaceuticals industry 18 other companies have achieved higher Revenue quarter on quarter growth. While Elutia Inc 's Revenue growth quarter on quarter, overall rank is 1937.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #19
Healthcare Sector #242
Overall #1937
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #19
Healthcare Sector #242
Overall #1937
Revenue Q/Q Growth Statistics
High Average Low
11.8 % -5.1 % -41.47 %
(Dec 31 2023)  


ELUT's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2023 Elutia Inc reported drop in Revenue from the previous quarter by -10.52% to $ 5.84 millions, from $ 6.53 millions achived in the previous reporting period.

Even seasonal factors which normally elevate III. Quarter 2023 Revenue, that clearly was not substantial to recover Biotechnology & Pharmaceuticals's company III. Quarter 2023 outcome, Mason King, an industry expert based in Boston pointed out and mentioned that average quarter on quarter Revenue growth is at -5.1% for the Biotechnology & Pharmaceuticals's company.

Within Biotechnology & Pharmaceuticals industry 18 other companies have achieved higher Revenue quarter on quarter growth. While Elutia Inc 's Revenue growth quarter on quarter, overall rank is 1937.


Elutia Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2024)
12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
Cumulative Revenue 12 Months Ending $ 28.19 $ 35.40 $ 41.54 $ 48.08 $ 50.74
Y / Y Revenue Growth (TTM) -44.44 % -28.03 % -12.34 % 3.45 % 10.31 %
Year on Year Revenue Growth Overall Ranking # 776 # 1262 # 217 # 0 # 0
Seqeuential Revenue Change (TTM) -20.36 % -14.77 % -13.62 % -5.24 % 3.16 %
Seq. Revenue Growth (TTM) Overall Ranking # 1223 # 1259 # 2036 # 0 # 0




Cumulative Revenue growth Comment
Elutia Inc 's cumulative 12 months Revenue continue to drop, but on the faster rate at -44.44% year on year, at Mar 31 2024 compare to the -28.03% decrease at Dec 31 2023. If the Elutia Inc 's fiscal year would end at Mar 31 2024, annual Revenue would be $28 millions.

In the Healthcare sector 165 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 776, from total ranking in previous quarter at 1262.

Revenue TTM Q/Q Growth Statistics
High Average Low
91.41 %
13.72 %
-44.44 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 15
Healthcare Sector # 166
Overall # 776

Revenue TTM Y/Y Growth Statistics
High Average Low
91.41 %
13.72 %
-44.44 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 15
Sector # 215
S&P 500 # 1223
Cumulative Revenue growth Comment
Elutia Inc 's cumulative 12 months Revenue continue to drop, but on the faster rate at -44.44% year on year, at Mar 31 2024 compare to the -28.03% decrease at Dec 31 2023. If the Elutia Inc 's fiscal year would end at Mar 31 2024, annual Revenue would be $28 millions.

In the Healthcare sector 165 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 776, from total ranking in previous quarter at 1262.

Revenue TTM Q/Q Growth Statistics
High Average Low
91.41 %
13.72 %
-44.44 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 15
Healthcare Sector # 166
Overall # 776

Revenue TTM Y/Y Growth Statistics
High Average Low
91.41 %
13.72 %
-44.44 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 15
Sector # 215
S&P 500 # 1223




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ELUT's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for ELUT's Competitors
Revenue Growth for Elutia Inc 's Suppliers
Revenue Growth for ELUT's Customers

You may also want to know
ELUT's Annual Growth Rates ELUT's Profitability Ratios ELUT's Asset Turnover Ratio ELUT's Dividend Growth
ELUT's Roe ELUT's Valuation Ratios ELUT's Financial Strength Ratios ELUT's Dividend Payout Ratio
ELUT's Roa ELUT's Inventory Turnover Ratio ELUT's Growth Rates ELUT's Dividend Comparisons



Companies with similar Revenue drop for the quarter ending Mar 31 2024 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2024
Collegium Pharmaceutical inc -0.21%$ -0.215 millions
Mettler Toledo International Inc-0.30%$ -0.300 millions
3m Company-0.35%$ -0.349 millions
Icu Medical Inc-0.42%$ -0.423 millions
Lifeloc Technologies Inc -0.51%$ -0.513 millions
Regeneron Pharmaceuticals Inc -0.54%$ -0.541 millions
Envista Holdings Corporation-0.62%$ -0.622 millions
Orgenesis Inc -0.70%$ -0.704 millions
Vyne Therapeutics Inc -1.01%$ -1.010 millions
Ge Healthcare Technologies Inc -1.50%$ -1.502 millions
Baxter International Inc -1.56%$ -1.562 millions
Y mabs Therapeutics inc -1.58%$ -1.580 millions
Pacific Biosciences Of California Inc -1.59%$ -1.589 millions
Cartesian Therapeutics Inc -1.65%$ -1.650 millions
Viatris Inc -1.76%$ -1.762 millions
Ocuphire Pharma Inc -2.17%$ -2.173 millions
Vaso Corporation-2.51%$ -2.513 millions
Dentsply Sirona Inc -2.56%$ -2.556 millions
Alpha Pro Tech Ltd -2.78%$ -2.775 millions
Prestige Consumer Healthcare Inc -2.82%$ -2.817 millions
West Pharmaceutical Services Inc -2.99%$ -2.986 millions
Integra Lifesciences Holdings Corp-3.14%$ -3.144 millions
Accelerate Diagnostics Inc -3.17%$ -3.165 millions
National Research Corporation-3.18%$ -3.180 millions
Catheter Precision Inc -3.53%$ -3.529 millions
Elanco Animal Health Inc-4.14%$ -4.137 millions
Ptc Therapeutics inc -4.66%$ -4.657 millions
Foghorn Therapeutics Inc -4.88%$ -4.879 millions
Aclaris Therapeutics Inc -5.14%$ -5.142 millions
Avantor Inc -5.65%$ -5.645 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com